Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCCLURANDOM: 177Lu-Octreotate vs Sunitinib in pNET
NCT02230176Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Feb 2015
- Primary completion
- Apr 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in Pancreatic neuroendocrine tumor (PanNET), sponsored by Gustave Roussy. Started Feb 2015; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02230176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02230176.